Experimental approach of chemotherapy for tuberculosis

被引:3
作者
Grosset, J
机构
来源
MEDECINE ET MALADIES INFECTIEUSES | 1996年 / 26卷 / 11期
关键词
tuberculosis; experimental chemotherapy; murine model;
D O I
10.1016/S0399-077X(96)80198-3
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Because of it is easy to handle in terms of size, supply, maintenance, robustness and reproducibility, the mouse infected with Mycobacterium tuberculosis and treated with antimicrobial drugs is the choice model for experimental chemotherapy on tuberculosis. It provides results that may be applied to man on the condition that age, race, body weight of mice are precisely defined as well as the strain of M. tuberculosis used (at best the H37Rv reference strain), the way its virulence is maintained and subcultures are made, In addition, because of the important pharmacokinetic differences between mice and man, antimicrobial drugs should be given to the mouse only at dosages equivalent to those given to man, at best in terms of AUC. Experimental methods to test the activity of a single drug are different from the methods used to test the activity of a drug combination, In the first case to prevent a possible interference with the selection of drug resistant mutants, either mice are infected with 5 x 10(3) cfu and the treatment starts two weeks later when the microbial population reaches 10(6) cfu or they infected with 10(6) cfu and the treatment starts on the day after infection. In the second case, mice are infected with 5 x 10(6) cfu and the treatment starts two weeks later when the microbial population reaches 10(8) cfu, Experimental chemotherapy for tuberculosis could lead to: possible improvements of the present short-course chemotherapy by further shortening the total duration of treatment or by increasing the intervals between drug administration; new regimens for the treatment of multidrug resistant tuberculosis; and curative and preventive treatment of tuberculosis in HIV-infected patients.
引用
收藏
页码:922 / 925
页数:4
相关论文
共 30 条
[1]  
[Anonymous], 2010, CLIN PHARMACOKINET
[2]   TUBERCULOSIS IN PATIENTS WITH HUMAN-IMMUNODEFICIENCY-VIRUS INFECTION [J].
BARNES, PF ;
BLOCH, AB ;
DAVIDSON, PT ;
SNIDER, DE .
NEW ENGLAND JOURNAL OF MEDICINE, 1991, 324 (23) :1644-1650
[3]  
CANETTI G, 1960, AM REV RESPIR DIS, V82, P295
[4]   PREVENTIVE THERAPY OF TUBERCULOSIS WITH RIFAPENTINE IN IMMUNOCOMPETENT AND NUDE-MICE [J].
CHAPUIS, L ;
JI, BH ;
TRUFFOTPERNOT, C ;
OBRIEN, RJ ;
RAVIGLIONE, MC ;
GROSSET, JH .
AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 1994, 150 (05) :1355-1362
[5]  
CULLITON BJ, 1992, NATURE, V356, P473, DOI 10.1038/356473a0
[6]  
DICKINSON J M, 1970, Tubercle, V51, P82, DOI 10.1016/0041-3879(70)90131-5
[7]  
FENNER F, 1951, AM REV TUBERC PULM, V64, P353
[8]   THE EMERGENCE OF DRUG-RESISTANT TUBERCULOSIS IN NEW-YORK-CITY [J].
FRIEDEN, TR ;
STERLING, T ;
PABLOSMENDEZ, A ;
KILBURN, JO ;
CAUTHEN, GM ;
DOOLEY, SW .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (08) :521-526
[9]  
GROSSET J, 1980, CLIN CHEST MED, V1, P231
[10]  
GROSSET J, 1978, REV FR MAL RESPIR, V6, P515